Skip to content
My WebMD Sign In, Sign Up

Bladder Cancer Health Center

Font Size

Bladder Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage I Bladder Cancer

Stage I bladder cancer is defined by the following TNM classification:

  • T1, N0, M0

Patients with stage I bladder tumors can be cured by a variety of treatments, even though the tendency for new tumor formation is high. In a series of patients with Ta or T1 tumors who were followed for a minimum of 20 years or until death, the risk of bladder recurrence following initial resection was 80%.[1] Patients at greatest risk of recurrent disease are those whose tumors are large, poorly differentiated, multiple, or associated with nuclear p53 overexpression.[2] In addition, patients with carcinomain situ (Tis) or dysplasia of grossly uninvolved bladder epithelium are at greater risk of recurrence and progression.[1,3,4]

Recommended Related to Bladder Cancer

Understanding Bladder Cancer -- Diagnosis and Treatment

To diagnose bladder cancer, your doctor completes a thorough medical history and examination. You will then be referred to a urologist, a physician who has special training in managing diseases of the bladder. The first test the urologist may perform is an intravenous pyelogram (IVP), followed by a cystoscopy. During a cystoscopy, the urologist will pass a cystoscope (a fiber-optic lighted tube) through the urethra in order to view the bladder. A urine sample for cytology will be obtained and a...

Read the Understanding Bladder Cancer -- Diagnosis and Treatment article > >

Transurethral resection (TUR) and fulguration are the most common and conservative forms of management. Careful surveillance of subsequent bladder tumor progression is important. One retrospective series addressed the value of performing a second TUR within 2 to 6 weeks of the first.[5][Level of evidence: 3iiDiv] A second TUR performed on 58 patients with T1 disease found that 14 patients (24%) had residual (T1) disease and 16 patients (28%) had muscle invasion (T2). Such information may change the definitive management options in these individuals.

Patients who require more aggressive forms of treatment are those with extensive multifocal recurrent disease and/or other unfavorable prognostic features. Segmental cystectomy is applicable to only a small minority of patients because of the tendency of bladder carcinoma to involve multiple regions of the bladder mucosa and to occur in areas that cannot be segmentally resected.

Intravesical therapy with thiotepa, mitomycin, doxorubicin, or bacillus Calmette Guérin (BCG) is most often used in patients with multiple tumors or recurrent tumors or as a prophylactic measure in high-risk patients after TUR. Administration of intravesical BCG combined with subcutaneous BCG following TUR was compared with TUR alone in patients with Ta and T1 lesions. Treatment with BCG delayed progression to muscle-invasive and/or metastatic disease, improved bladder preservation, and decreased the risk of death from bladder cancer.[6,7]

A randomized study of patients with superficial bladder cancer also reported a decrease in tumor recurrence in patients given intravesical and percutaneous BCG compared with controls.[8] Two, nonconsecutive, 6-week courses with BCG may be necessary to obtain optimal response.[9] Patients with a T1 tumor at the 3-month evaluation after a 6-week course of BCG and patients with Tis that persists after a second 6-week BCG course have a high likelihood of developing muscle-invasive disease and should be considered for cystectomy.[9,10,11] A randomized study that compared intravesical and subcutaneous BCG to intravesical doxorubicin showed better response rates and freedom from recurrence with the BCG regimen for recurrent papillary tumors as well as for Tis.[12] Preliminary results of one study have shown a possible survival benefit with maintenance BCG after a 6-week induction course.[13] Another study that compared alternating mitomycin and BCG with BCG alone, both given for 24 months, found that the efficacy was equal, but that the side effects of the combined regimen were slightly less.[14][Level of evidence: 1iiDiii] A similar trial comparing sequential mitomycin and BCG to mitomycin alone also found no major differences in toxic effects or efficacy.[15][Level of evidence: 1iiDiii] A randomized trial from the Swedish-Norwegian Bladder Cancer Group compared 2 years of intravesical treatment with mitomycin C versus BCG for patients at high risk for recurrence or progression. At 5 years, a significant improvement was noted in disease-free survival with BCG (P = .04); however, no difference was observed in tumor progression or overall survival between the two arms.[16]

1|2

WebMD Public Information from the National Cancer Institute

Last Updated: February 25, 2014
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
Next Article:

Today on WebMD

Integrative Medicine Cancer Quiz
QUIZ
what is your cancer risk
HEALTH CHECK
 
cancer fighting foods
SLIDESHOW
Bladder Cancer Why More Men May Be At Risk
VIDEO
 
Lifestyle Tips for Depression Slideshow
SLIDESHOW
Bladder Sparing Cancer Treatment
VIDEO
 
Vitamin D
SLIDESHOW
Pets Improve Your Health
SLIDESHOW
 

WebMD Special Sections